Cargando…

A Novel Nomogram for Identifying the Patients at Risk for Rapid Progression of Advanced Hormone-Sensitive Prostate Cancer

PURPOSE: The goal of this study was to assess the prognostic impact of the lower urinary tract symptoms (LUTS) in advanced prostate cancer (PCa) patients before progression to castration-resistant prostate cancer (CRPC). METHODS: A retrospective analysis of the follow-up data for 152 CRPC patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Mingshuang, Pan, Chenxi, He, Yi, Yang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516215/ https://www.ncbi.nlm.nih.gov/pubmed/37746314 http://dx.doi.org/10.2147/CMAR.S425181

Ejemplares similares

Identifying Patients With Rapid Progression From Hormone-Sensitive to Castration-Resistant Prostate Cancer: A Retrospective Study
por: Pan, Chenxi, et al.
Publicado: (2023)

Analysis of Baseline Serum Lipid Profile for Predicting Clinical Outcomes of Patients with Extensive-Stage Small Cell Lung Cancer
por: Wu, Mingshuang, et al.
Publicado: (2023)

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer
por: Hou, Xiaoyu, et al.
Publicado: (2012)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
por: Tamada, Satoshi, et al.
Publicado: (2018)

Establishment of a Novel Combined Nomogram for Predicting the Risk of Progression Related to Castration Resistance in Patients With Prostate Cancer
por: Li, Shuqiang, et al.
Publicado: (2022)

Survival Analysis and a Novel Nomogram Model for Progression-Free Survival in Patients with Prostate Cancer
por: Han, Yuefu, et al.
Publicado: (2022)

Changes in phospholipid metabolism in exosomes of hormone-sensitive and hormone-resistant prostate cancer cells
por: Yi, Xianlin, et al.
Publicado: (2021)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2015)

The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer
por: Meng, Jialin, et al.
Publicado: (2019)

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy
por: Tatenuma, Tomoyuki, et al.
Publicado: (2023)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer
por: Feng, Dechao, et al.
Publicado: (2022)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020)

Prognostic Nomogram For Locoregionally Advanced Nasopharyngeal Carcinoma
por: Jiang, Yanming, et al.
Publicado: (2020)

Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report
por: Li, Ke-Hao, et al.
Publicado: (2022)

CT-Based Radiomics Nomogram for Prediction of Progression-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yan, Chang, et al.
Publicado: (2021)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

Cross-Tissue Analysis Using Machine Learning to Identify Novel Biomarkers for Knee Osteoarthritis
por: Zhao, Yudong, et al.
Publicado: (2022)

Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy
por: Cormio, Luigi, et al.
Publicado: (2018)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
por: Shenoy, Niraj, et al.
Publicado: (2016)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Metastatic hormone-sensitive prostate cancer: How should it be treated?
por: López-Campos, Fernando, et al.
Publicado: (2021)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer
por: Xu, Chaojie, et al.
Publicado: (2023)

A Novel Nomogram Based on Initial Features to Predict BPH Progression
por: Luciani, Lorenzo G., et al.
Publicado: (2022)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
por: Kim, Jong-Kwang, et al.
Publicado: (2021)

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer
por: Ma, Bing-Lei, et al.
Publicado: (2019)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Nomogram to predict rapid kidney function decline in population at risk of cardiovascular disease
por: Zhang, Qiuxia, et al.
Publicado: (2022)

Novel hormonal therapies in the management of advanced prostate cancer: extrapolating Asian findings to Southeast Asia
por: Ong, Teng Aik, et al.
Publicado: (2023)

Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI’s “big data for better outcomes” program
por: Gomez Rivas, Juan, et al.
Publicado: (2023)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

Development of a nomogram to predict progression-free survival in patients with locally advanced renal cell carcinoma
por: Xiao, Ruo-Tao, et al.
Publicado: (2021)

Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer
por: Hu, Meichun, et al.
Publicado: (2015)

A novel nomogram predicting the risk of positive biopsy for patients in the diagnostic gray area of prostate cancer
por: Hou, Guang-Dong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_em9sq3b1fut55rv4feqc4u94em